Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Takehiro Nakao"'
Autor:
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101482- (2024)
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine
Externí odkaz:
https://doaj.org/article/531ab3d12ed3433ea0a6a2a65cf6a74f
Autor:
Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Cancer Medicine, Vol 12, Iss 11, Pp 12095-12105 (2023)
Abstract Background Since it was first reported in December 2019, coronavirus disease 2019 (COVID‐19) spread rapidly across the globe resulting in a pandemic. As of August 2022, seven outbreak peaks have been confirmed in Tokyo, and the numbers of
Externí odkaz:
https://doaj.org/article/c0255b117bae403e9d5e854df13ba152
Autor:
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Publikováno v:
Breast, Vol 61, Iss , Pp 136-144 (2022)
Background: The previous second-line treatment for HER2-positive metastatic breast cancer were ado-trastuzumab emtansine (T-DM1); however, its activity is decreased in tumors with heterogenous, reduced, or loss of HER2 expression. Trastuzumab deruxte
Externí odkaz:
https://doaj.org/article/d024404aa0a9446f8558c9fcac6f4da6
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Yoko Fukasawa, Kanako Mamishin, Ayumi Komuro, Mashiro Okunaka, Chihiro Kondoh, Kenichi Harano, Takahiro Kogawa, Nobuaki Matsubara, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Breast, Vol 58, Iss , Pp 50-56 (2021)
Background: Visceral crisis in metastatic breast cancer (MBC) is defined as severe organ dysfunction requiring rapidly efficacious therapy. Although weekly paclitaxel plus bevacizumab (wPTX + BV) achieves a high response rate in human epidermal growt
Externí odkaz:
https://doaj.org/article/1ee0cb78f98046edb5ecc170618af845
Autor:
Kaori Kawakami, Yuria Tanaka, Yuji Ikeda, Atsushi Komatsu, Osamu Kobayashi, Takahiro Nakajima, Takehiro Nakao, Chiaki Takeya, Mikiko Asai-Sato, Fumihisa Chishima, Misako Iwata, Kei Kawana
Publikováno v:
Clinical and Experimental Obstetrics & Gynecology, Vol 48, Iss 2, Pp 317-322 (2021)
X-ray pelvimetry is used for evaluation of pelvic inlet generally to diagnose cephalopelvic disproportion (CPD) or contracted inlet. Cesarean section delivery (C/S) is often performed for labor dystocia without CPD or contracted inlet. We examined wh
Externí odkaz:
https://doaj.org/article/5dda524b8cc442c3a389ec4440924dda
Autor:
Chikako Funasaka, Yoichi Naito, Shota Kusuhara, Takehiro Nakao, Hiromichi Nakajima, Megumi Kawamoto, Kaede Baba, Kanako Mamishin, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Ako Hosono, Tomoaki Sasaki, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Japanese Journal of Clinical Oncology. 53:105-114
Background Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are the standard treatment for advanced hormone receptor-positive breast cancer. Although interstitial lung disease is a rare (1–3.3%) but serious adverse event associated with CDK4/6 inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1104059874437cc3479bc7074f648fcc
https://doi.org/10.1093/jjco/hyac168
https://doi.org/10.1093/jjco/hyac168
Autor:
Mao Uematsu, Hiromichi Nakajima, Ako Hosono, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Tetsuo Akimoto, Toru Mukohara
Publikováno v:
Melanoma Research; Dec2023, Vol. 33 Issue 6, p547-552, 6p
Autor:
Kaede Baba, Megumi Kawamoto, Kanako Mamishin, Mao Uematsu, Hikari Kiyohara, Akira Hirota, Nobuyuki Takahashi, Misao Fukuda, Shota Kusuhara, Hiromichi Nakajima, Chikako Funasaka, Takehiro Nakao, Chihiro Kondoh, Kenichi Harano, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Toshikatsu Kawasaki, Toru Mukohara
Publikováno v:
Cancer Medicine.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cab37de0d375c2e8a1e6fe0122e4c783
https://doi.org/10.1002/cam4.5898
https://doi.org/10.1002/cam4.5898
Autor:
Mitsutake Yano, Kaei Nasu, Masanori Yasuda, Tomomi Katoh, Masahiro Kagabu, Hisanori Kobara, Motoki Matsuura, Osamu Tokuyama, Takaharu Yamawaki, Senn Wakahashi, Tomoko Noguchi, Kaoruko Mizuno, Keiji Shitsukawa, Yoshimasa Onohara, Takashi Nakabori, Aki Miyasaka, Takehiro Nakao, Tatsuya Matsunaga, Yusuke Kunimi, Manabu Sakurai, Aya Uchiyama, Ryoji Itoh, Nobuyuki Ohike, Takashi Hirakawa, Tadashi Watanabe, Koji Nishino, Takashi Motohashi, Kimihiko Ito
Publikováno v:
Melanoma Research. 32:150-158
The objective of this study was to propose prognostic factors and optimal treatment strategies by analyzing the clinicopathological features and programmed death-ligand 1 (PD-L1) expression. We analyzed 31 patients diagnosed with uterine or ovarian m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6da4ad6346953e6b454330bd48cc4747
https://doi.org/10.1097/cmr.0000000000000811
https://doi.org/10.1097/cmr.0000000000000811
Autor:
Yoko Fukasawa, Nobuaki Matsubara, Chihiro Kondoh, Takehiro Nakao, Shota Kusuhara, Katsuya Tsuchihara, Takeshi Kuwata, Akiko Nakayama, Ako Hosono, Chikako Funasaka, Yoichi Naito, Sachiyo Mimaki, Toru Mukohara, Kenichi Harano
Publikováno v:
Oncologist
Somatic mutations in human epidermal growth factor receptor 2 (HER2) are present in approximately 3% of breast cancers. Some HER2 mutations are activating, and they represent a mechanism of resistance to conventional anti-HER2 therapies such as trast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d859355c23eac21b8a380da2ace89a8
https://doi.org/10.1002/onco.13715
https://doi.org/10.1002/onco.13715